| Factor Information | |
|---|---|
| Data ID | 3845 |
| Factor | Plasma TXB2 levels |
| Description | Among the Rp < or = 10 patients, the plasma TXB2 levels were significantly higher in the dyspnea(+) group than in the dyspnea(-) group (P < .0001). |
| Biomarker | NA |
| Classification | E2 (physiological factor - biochemical index) |
| Association | |
|---|---|
| Application | risk assessment |
| Objective | In the present study, we measured the plasma TXB2 concentration to evaluate platelet activation in patients with pulmonary hypertension and congenital heart disease. |
| p Value | <0.0001 |
| Conclusion | Among the Rp < or = 10 patients, the plasma TXB2 levels were significantly higher in the dyspnea(+) group than in the dyspnea(-) group (P<0.0001) |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 715 |
| CHD Type | isolated CHD/non-isolated CHD |
| CHD Subtype | VSD/VSD, ASD/VSD, CoA/VSD, PDA/AS/PDA/DORV/CAVC/TOF, PA/ECD, PDA/EA/other |
| Reference | |
|---|---|
| PMID | 7994842 |
| Year | 1994 |
| Title | Plasma thromboxane B2 concentration in pulmonary hypertension associated with congenital heart disease |
| Sample | ||
|---|---|---|
| Population | children | |
| Source | Blood | |
| Region | Osaka, Japan | |
| Method | Informed consent to the study was obtained from the patients or their parents | |
| Race | Asian | |
| Disease History | N/A | |
| Treatment History | cardiac catheterization | |
| Group | dyspnea(+) group(Treatment) | dyspnea(-) group(Control) |
| Number | 14 | 45 |
| Age | 0.9±0.8 years | 3.7±6.4 years |
| Gender (Male: Female) | 11:3 | 25:20 |
| Marker Level | 957.5±486.8 pg/mL | 145.1±87.5 pg/mL |
